The protection of telomeres 1 protein (POT1) is a critical component of the shelterin complex, a multiple-protein machine that regulates telomere length and protects telomere ends. Germline variants in POT1 have been linked to familial melanoma, and somatic mutations are associated with a range of cancers including cutaneous T-cell lymphoma (CTCL).
A bout 10% of patients with melanoma have a family history of the disease. 1, 2 The major melanoma predisposition genes are CDKN2A, CDK4, and BAP1. 1 Extremely rare germline variants in the TERT promoter have also been reported. 3, 4 More recently, components of the shelterin complex, including in the Protection of Telomeres 1 (POT1) gene, ACD, and TERF2IP, [5] [6] [7] have been implicated. Pathogenic POT1 variants promote telomere lengthening and disrupt telomere stability. 5, 6 Importantly, these variants are rare and potentially contribute to 1% to 5% of familial melanoma cases. 5, 6 Pathogenic POT1 variants have also been associated with predisposition to chronic lymphocytic leukemia (CLL), cardiac angiosarcoma, glioma, and, more recently, colon cancer.
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Methods
Institutional review board approval for this study was obtained from the University of Leeds, University of Michigan, Hospital Clínic de Barcelona, and Gustave Roussy. All patients included in this study signed informed consent. Exome capture was performed using the SureSelect XT Human AllExon V5 platform (Agilent Technologies Inc), and sequencing was performed using the Illumina HiSeq 2000 platform (Illumina Inc). Telomere binding and length assays were performed as previously described. 5 For analysis methods, see the Supplement.
Results
Our analysis began with the identification of a North American proband who had developed primary melanoma at age I78T   I78T  I78T   I78T   I78T  I78T   I78T I78T WT
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In this proband and all 3 family pedigrees, the POT1 p.I78T variant was identified as the likely pathogenic variant; all 3 pedigrees show the same base change. A, Locations of lesions identified and excised from the proband, a POT1 variant carrier (p.I78T, c.233T>C, chromosome 7, g.124870933A>G, GRCh38) at age 31 years. The primary melanoma on the neck was from the proband's father, not the proband, but is added here to illustrate its position. This melanoma progressed to metastatic disease in the father. All numbered lesions were sequenced. Samples numbered 550/551, 554/555, and 609/610 indicate 2 samples taken from the same lesion in these 3 cases. B, Pedigree structures for all families identified to carry the p.I78T variant. Pedigree 1 corresponds to that of the proband, and pedigrees 2 and 3 were identified from the GenoMEL Consortium. Individuals represented by black shapes are variant carriers who presented with melanoma. Individuals with no genotype were not tested. Ages, reported in years, at the times of cancer diagnoses are shown in parentheses when available.
31 years along with multiple dysplastic and compound and dermal nevi ( Figure 1A ). He had also developed cutaneous T-cell lymphoma (CTCL) and CLL and at ages 29 and 40 years, respectively. His father had developed CTCL, CLL, melanoma in situ, and melanoma at ages 58, early 60s, 72, and 74 years, respectively ( Figure 1B , pedigree 1). The proband had sequenced his own genome on a nextgeneration platform and had identified a POT1 variant (p.I78T, c.233T>C, chromosome 7, g.124870933A>G, GRCh38), the pathogenicity of which was unknown, but it was predicted to be damaging by SIFT (score 0) 9 and Polyphen-2 (score 1.0) 10 analysis. To determine the frequency of this variant in melanoma families, we ascertained cases by consulting The Melanoma Genetics Consortium (GenoMEL, http://www.genomel.org) and found 2 more carrier families; one of Spanish ancestry (1 case among 171 families) ( Figure 1B , pedigree 2; more detail on the Spanish pedigree will be published elsewhere) and the other of French descent 6 (1 case among 157 families) ( Figure 1B , pedigree 3), both of whom had tested negative for other high-penetrance genes (eMethods in the Supplement). We next investigated whether the p.I78T variant had a functional effect. An analysis of orthologous protein sequences spanning 450 million years of evolutionary distance showed complete conservation of the isoleucine at position 78 (Figure 2A) , and the protein model showed that this residue is in close proximity to arginine 137, another position found to be mutated in melanoma pedigrees ( Figure 2B) . 6 This suggested that alteration of this residue might impair POT1 single-stranded DNA binding.
To test this, we generated a POT1 complementary DNA (cDNA) construct encoding the POT1 p.I78T protein and found that it was severely impaired for its ability to bind to a polynucleotide telomere-like probe (IR700-GGTTAGGGTTAGGGTTAGGG) ( Figure 2C ), as previously seen with established melanoma-predisposing alleles. 5 To provide further functional proof, we transduced 
A, Multiple sequence alignment of the protection of telomeres 1 (POT1) protein sequence in humans and 9 other species. Shown are amino acid positions 69 to 88, relative to human POT1, with the red arrow indicating the highly conserved I78 residue. The best match in each protein alignment relative to human protein is shown. B, The location of the I78 residue on the structure of the POT1 oligonucleotide/oligosaccharide-binding fold (OB) domain is indicated, alongside another residue previously described as mutated in melanoma families (R137). Green ribbons represent the OB domains; orange thread, the telomere-like sequence. C, Telomere gel shift assays show that the POT1 p.I78T
protein is unable to bind to a telomere-like sequence. Wild-type (WT) POT1, POT1 Y89C (a known pathogenic/disruptive variant) and POT1Δ (OB domain deletion) constructs were used as controls. 5 TNT1 and TNT2 indicate separate in vitro translation reactions; pcDNA3 is an empty vector control. The arrow indicates the presence of a POT1 protein-telomere complex formed by the binding of in vitro translated POT1 protein to a telomere-like probe. Disruption of this protein-DNA complex is associated with telomere instability and a loss of telomere length control.
telomerase-positive HT1080 cells with either wild-type or p.I78T POT1 cDNA constructs and cultured them through 45 population doublings. Telomeres in cells expressing the p.I78T POT1 cDNA were elongated compared with cells expressing wild-type POT1 (eMethods and eFigure 1 in the Supplement).
After identifying 3 apparently unrelated families living in different countries carrying the POT1 p.I78T variant, we genotyped individuals using CoreExome single-nucleotide polymorphism arrays (Illumina Inc) to estimate the coefficient of relatedness between carriers of the variant from different families and performed an analysis that suggested no recent co-ancestry between the families. We were also able to confirm the reported genetic relationships within each family. Although the families were not closely related, the sharing of genotypes around the POT1 gene in p.I78T variant carriers was consistent with a common haplotype across some 4 megabase pairs (Mb) upstream and downstream of the variant, suggesting that the p.I78T variant is a founder event.
Interestingly, all 3 families self-reported being Jewish, and we noted that the chromosome 7 g.124870933A>G change has been reported in 3 individuals of Ashkenazi Jewish descent in the Genome Aggregation Database (gnomAD; chromosome 7 g.124510987A>G in GRCh37; allele frequency in the Ashkenazi Jewish population, 0.0003105; in all other populations, 0.000004305).
11 Since patients with germline POT1 variants are highly predisposed to melanoma development, we wondered if there would be any defining features of the somatic landscape of melanocytic lesions in these patients. Thus, we whole-exome sequenced 30 previously excised, formalin-fixed, paraffin-embedded nevi from the proband in pedigree 1 ( Figure 1 ) and a large malignant melanoma from the proband's father (anatomic location illustrated in Figure 1A ; eMethods in the Supplement). Hotspot NRAS (Q61L, Q61K and Q61R) and BRAF (V600E, V600D) mutations were identified in nevi, and the melanoma was found to be KIT L576P positive and to carry truncating NF1 and RASA2 mutations (eTable 1 in the Supplement), suggesting a prominent role for the MAPK pathway. No TERT promoter mutations were found. Since a major driver of melanoma formation is exposure to UV light, we next attempted to identify the imprint of this mutagen on the melanoma genome. This analysis revealed an average of 40.67 somatically acquired mutations per Mb of exome, of which 87% were C>T/G>A mutations. Extraction of mutation signatures from the melanoma and nevi mutation catalogs identified the UV-associated signature 7 (cosine similarity, 0.97).
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The number of mutations we identified in the father's melanoma ( Figure 1B , pedigree 1) was higher than the average observed following an analysis of 318 melanomas (16.8 mutations/Mb) sequenced by The Cancer Genome Atlas (TCGA), 13 suggesting a contribution from UV light to melanomagenesis in this POT1 mutation carrier. The exome sequence of the CLL from the proband of pedigree 1 ( Figure 1B ) revealed few somatic mutations and no enrichment for C>T mutations (Figure 3 ;e T a b l e2i nt h e Supplement). All of the carriers in pedigrees 2 and 3 ( Figure 1B ) who had presented with melanoma had been diagnosed with either superficial spreading or nodular cutaneous melanoma. A histopathological analysis of the melanoma from the p.I78T variant carrier (father, pedigree 1, Figure 1B ) revealed that there were no defining features distinguishable from sporadic melanoma (eFigure 2 in the Supplement).
Discussion
The identification of pathogenic germline variants is of critical importance because it informs genetic counselling and allows individuals at high risk to be prioritized for surveillance programs. In this study, we identified the POT1 p.I78T variant in 3 unrelated melanoma pedigrees, with evidence for the presence of this allele at a higher frequency among Ashkenazi Jews. Interestingly, only 1 founder allele (p.V59G; CDKN2A) has previously been associated with melanoma risk in people of Jewish heritage.
14 Notably, as illustrated in Figure 1B , in addition to melanoma, members of pedigree 1 have been diagnosed with both CTCL and CLL, while pedigree 2 contains a variant carrier who developed melanoma and thyroid cancer. Collectively, this clinical picture may suggest that this variant contributes to a range of cancers. Indeed, somatic POT1 p.I78T mutations have been found in a case of ovarian cancer (COSMIC ID: COSM116403) and in a case of hepatosplenic T-cell lymphoma. 
Limitations
Our study ascertained cases from GenoMEL, meaning that we may not have a full picture of the spectrum of cancers acquired by variant carriers. Additionally, while 4 of the 8 variant carriers illustrated in Figure 1B have developed melanoma, 4 variant carriers in pedigree 2 have not yet presented with melanoma or any other malignancy, and these individuals were 19, 25, 50, and 55 years old, respectively, at last followup. Thus, the penetrance of melanoma and other cancers in p.I78T variant carriers is yet to be defined. Ultimately the identification of further pedigrees with the p.I78T variant will help define its role in tumorigenesis.
Conclusions
The germline POT1 p.I78T variant is a candidate predisposition allele for melanoma development because it disrupts POT1-telomere binding and promotes telomere lengthening. Screening for this variant could be considered in individuals found to be negative for pathogenic variants in established melanoma predisposition genes such as CDKN2A, BAP1, and CDK4, particularly in families of Jewish heritage and/or with additional POT1-associated cancers such as CTCL and CLL. Mutations were identified from whole-exome sequencing of a chronic lymphocytic leukemia (CLL) sample from the proband and a melanoma from the proband's father (pedigree 1). Included are missense, synonymous, nonsense, and translational start mutations. Mutation  C>A  C>G  C>T  T>A  T>G  T>C  CLL  0  2  8  0  0  2  Melanoma  31  31  1597  54  40 corresponding to the neck lesion in Figure 1A , invading deeply into the dermis with ulceration. B)
Formalin-fixed paraffin-embedded slide of this specimen.
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eMethods
Previous screening for mutations in established high-penetrance melanoma genes
All patients had been screened and found negative for mutations in CDKN2A, BAP1 and CDK4. The patients in pedigrees 1 and 2 were also negative for the MITF E318K variant.
Whole exome sequencing
Whole exome sequencing was performed on DNA from 30 nevi, 3 normal skin samples, normal blood and a CLL sample from the proband, and a melanoma and normal blood sample from the proband's father (Figure 1, pedigree 1 alignments, supplementary alignments, and reads failing Illumina chastity filtering, the mean sequencing depth was 126x (range 73-171x). These 'clean' BAMs were used to identify somatic mutations using MuTect (version 1.1.7, 3 ) with default parameters. The nevi and CLL were compared to the proband's normal blood, and the father's blood sample was used as the matched normal for the father's melanoma (pedigree 1, Figure 1 ). In the variant calls from the FFPE nevus samples, we observed a high proportion of C>T/G>A mutations with low variant allele fractions (VAF). Mutation signature analysis using SomaticSignatures 4 (version 2.6.0) revealed that the majority of these were due artefacts generated from 5-methylcytosine (5mC) deamination. In the variant calls from the FFPE melanoma sample, a high number of C>T/G>A mutations were present at both high and low VAF, and the dominant mutation signature present was associated with UV-damaged DNA (Alexandrov signature 7, 5 ). In contrast, the CLL sample from blood had very few mutations and no C>T/G>A bias. Thus, to reduce artefacts, somatic mutations were removed from the FFPE sample mutation catalogue if one of the following was true: the coverage at the site in the lesion/cancer was less than 10, the VAF was less than 0.05, the VAF was less than 0.15 with 5 or less supporting reads, or the VAF was less than 0.20 and the total depth was less than 20. Analysis of the remaining mutation calls revealed the presence of signature 7 in several nevus samples, while other samples had too few mutations for a signature analysis. However, with this additional filtering, some mutations in known hotspot positions (in NRAS) were lost due to low cellularity in the DNA samples. Thus, the number of hotspot mutations we report might be an underestimate of the true mutation frequency for the reasons outlined above.
Capillary sequencing
All p.I78T mutation carriers were confirmed using capillary sequencing. PCR products for sequencing were amplified with the primers I78T_For: CATTTCTGGGGAATGAAAGC and I78T_Rev: AACTTGCCTGCTCTTTAGTGG.
Genotyping arrays
Illumina CoreExome arrays were used to genotype individuals from pedigrees 1-3 using the method described by the manufacturer.
Telomere gel shift assay POT1-telomere gel shift assays were performed as described previously 6 . POT1 WT, Y89C, I78T and POT1∆ cDNA constructs were synthesized by GeneArt and fully sequencevalidated.
